Skip to main content
Have a personal or library account? Click to login
Hepatocerebral Degeneration or Valproate Toxicity Cover

Hepatocerebral Degeneration or Valproate Toxicity

Open Access
|Jan 1993

Full Article

Six children with refractory seizures and focal neuronal damage who died of liver failure are reported from the Washington University School of Medicine, St Louis, MO. Four were treated with valproic acid (VPA) and developed liver failure within 30 - 68 days. Two of these children each had one sibling who was not exposed to VPA and developed the same clinical picture, but liver failure was delayed. Siblings receiving VPA survived only 3 and 5 months after onset of seizures, whereas those not treated with VPA lived for 7 to 16 months. [1]

COMMENT. The authors propose that many of the reported patients with VPA-associated hepatotoxicity represent undiagnosed hepato-cerebral degeneration, the Huttenlocher variant of Alpers’ syndrome. Their experience suggests that liver failure is accelerated by exposure to VPA, and an alternative antiepileptic treatment should be employed in young children with resistant seizures and mental and motor regression, indicative of cerebral degeneration. Recurrence of this syndrome in family members suggests an autosomal recessive inheritance, but the biochemical basis remains undetermined. Of 13 similar cases reported from the Hospital for Sick Children, London [2], only 4 had received VPA and 2 may have died from VPA-hepatotoxicity.(See Ped Neur Briefs July1987)

Language: English
Page range: 7 - 8
Published on: Jan 1, 1993
Published by: Pediatric Neurology Briefs Publishers
In partnership with: Paradigm Publishing Services

© 1993 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.